Digestive and Liver Health

Our mission is to provide you with personalized, high-quality, cost-effective care. Dr. Avalos founded Miami Gastro on the vision that healthcare should be equitable, accessible, and high quality. 

We are focused on changing healthcare outcomes and we can only do this if we actively measure our performance. Colon cancer is the 3rd leading cancer in the U.S. and the 2nd leading cause of cancer-related deaths. Colon cancer stems from precursors lesions known as adenomatous polyps. The gastroenterology societies understand that a quality indicator against colon cancer is to measure a proceduralist's adenoma detection rate (ADR). In other words, the proceduralist's ability to detect polyps is the most important indicator in the quality of a screening colonoscopy.  Joint societies (AGA, ACG, ASGE) in gastroenterology recommend that a proceduralist should accomplish a 25% adenoma detection rate for men and women. In other words, a proceduralist should be able to identify at least 1 adenoma (polyp) in 25 of 100 patients who undergo an average risk screening colonoscopy.  The risk of colorectal cancer is reduced when a patient has a colonoscopy with a "high detector". 

Dr. Avalos inputs his outcomes into the GIQuIC Registry (a national database that collects quality indicators in colonoscopy) and consistently achieves detection rates above 40% compared with the national accepted standard of 25%.  Dr. Avalos believes that we can only improve healthcare outcomes when we strive towards providing the highest quality colonoscopy in each of his patients.